Nature Communications

PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial

2025-12-15

Full text

DOI https://doi.org/10.1038/s41467-025-67262-x